Biological Biooncology

Alecensa

Payments companies reported to CMS as associated with Alecensa. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$415Kassociated payments (2023-2025)

2,952clinicians with associated payments

5companies reporting

By year

2023 $135K

2024 $206K

2025 $74K

Payments reported as associated with Alecensa, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Medical Oncology $153K

Hematology & Oncology $114K

Thoracic Surgery (Cardiothoracic Vascular Surgery) $58K

Internal Medicine $16K

Family $13K

Nurse Practitioner $11K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Alecensa

These are the largest totals companies reported as associated with Alecensa. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Mark Socinski	Orlando, FL	Hematology & Oncology	$31,450.62
Nasser Altorki	New York, NY	Thoracic Surgery (Cardiothoracic Vascular Surgery)	$20,763.22
Fadi Braiteh	Las Vegas, NV	Medical Oncology	$17,211.60
Stephen Liu	Los Angeles, CA	Medical Oncology	$14,628.62
Randeep Sangha	Sacramento, CA	Medical Oncology	$11,111.93
Melissa Johnson	Nashville, TN	Medical Oncology	$9,286.05
Jay Lee	Los Angeles, CA	Thoracic Surgery (Cardiothoracic Vascular Surgery)	$9,178.80
Carl Gay	Houston, TX	Internal Medicine	$8,943.33
Rosalyn Juergens	Hamilton	Medical Oncology	$8,887.72
Vincent Lam	Baltimore, MD	Medical Oncology	$8,886.61

Prescribed Alecensa?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.